Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
1993 (US FDA)
|
| gptkbp:ATCCode |
N06DA01
|
| gptkbp:brand |
gptkb:Cognex
|
| gptkbp:CASNumber |
321-64-2
|
| gptkbp:chemicalFormula |
C13H14N2
|
| gptkbp:color |
yellow
|
| gptkbp:discoveredBy |
Adrien Albert
|
| gptkbp:hasSMILES |
C1CNCC2=CC=CC=C2N1
|
| https://www.w3.org/2000/01/rdf-schema#label |
tacrine
|
| gptkbp:IUPACName |
1,2,3,4-tetrahydroacridin-9-amine
|
| gptkbp:KEGGID |
D08514
|
| gptkbp:legalStatus |
withdrawn in many countries
|
| gptkbp:mechanismOfAction |
gptkb:acetylcholinesterase_inhibitor
|
| gptkbp:meltingPoint |
173-175 °C
|
| gptkbp:MeSH_ID |
D013601
|
| gptkbp:molecularWeight |
198.27 g/mol
|
| gptkbp:PubChem_CID |
1935
CHEMBL105 DB00382 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea hepatotoxicity |
| gptkbp:synonym |
THA
tetrahydroaminoacridine |
| gptkbp:UNII |
N9YNS0M02X
|
| gptkbp:usedFor |
treatment of Alzheimer's disease
|
| gptkbp:withdrawn |
2013 (US)
|
| gptkbp:bfsParent |
gptkb:CYP1A2
|
| gptkbp:bfsLayer |
5
|